Back to results
US 12,214,036 B2Granted
Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
AssigneeIncyte Corporation
InventorsJonathan Rios-Doria, Holly K. Koblish
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating cancer by administering a compound, which is an AXL/MER kinase inhibitor, in combination with an antibody, or an antibody fragment thereof, that binds to PD-1.
Claims17
A method of treating cancer in a patient, comprising administering to said patient:
- (i) Compound 1, having the structure:
- or a pharmaceutically acceptable salt thereof;
- and
- (ii) an antibody, or an antigen-binding fragment thereof, that binds to human PD-1, wherein the antibody, or the antigen-binding fragment thereof comprises a variable heavy (VH) domain and a variable light (VL) domain, wherein the VH domain comprises the amino acid sequence set forth in SEQ ID NO:4 and the VL domain comprises the amino acid sequence set forth in SEQ ID NO:5;
- wherein the cancer is colorectal cancer.
2 more elements
Dependencies are inferred from the claim text.